I don't buy it at least they have not been spending more for the last 2 months. Will they spend more next month or the months after? Only time will tell. I think Eisai is out of their league and lacks the expertise to get this job handled.
We have a great product licensed to a partner that is facing financial crisis, does not have the money to expand world wide. Has cut it marketing staff in half and has cut advertising evidenced by facts. After guiding they were going to focus and aggressively go after the consumer instead of the doctors market, basically admitting their educate the doctors yielded little results. They clearly don't have the capital to try and get back into EU right now, they have been "planning their strategy to move forward Belviq forward in the EU" for almost 2 years now.
Belviq is going to be successful on its own given enough time. The word of mouth and social media has more to do with its success then Eisai as we sit here today.
Supporting Eisai when it is clear they are over their heads and don't have the horsepower to get this handled is reckless and a violation of their fiduciary to Arena shareholders. We have had to dilute because of Eisai and if they don't get their act in gear we may have to again. Eroding even more value from existing shareholders.
It was a joke because I am tired of hearing all of the plans to plan to move forward. At some point tomorrow has to come and the plan has to be executed..
Answer. We are planning a CC to address those concerns and will do so after we have meet to plan when that CC will be and what we plan to address in that meeting.
How much do we pay this person?
I think Craig Audit should be fired as the Global Regulatory guy he was a total failure. He has lied to shareholders and mis lead them on many occasions. No need to have the expense and we need someone there that can actually get something accomplished... not just talk about getting things accomplished.
No buyout, no change of marketing partner. Arena is happy with the blind leading the blind and are still shamelessly supporting Eisai at the expense of their shareholders.
That is exactly what this meeting was. Blah Blah Blah, we are working and planning on moving forward and very excited about our future.
Actually took a log in code emailed to you to get into this meeting... That was a first for Arena dog and pony show.
6 minutes before the meeting and no PR, this is going to be a dog and pony show again. Better have something of value to say.....
of that.. No PR out which is very telling.
If we get no PR's up into the meeting then nothing new will be discussed and it will be the same old dog and pony BS that has happened for years. Belviq is the first new and novel weight loss drug and we are excited, really really excited. Our pipeline is exciting too and we should be starting to move into clinical studies shortly, very soon, very very soon, just around the corner. Thank you.
Ok ok that was bad. I digress. I am expecting nothing new, obviously. Would love to be wrong or surprised tho.
But while Eisai was slow and made some big mistakes. Belviq is the real deal and the success of those on this wonderful drug are changing their lives. We are now scripting at a rate of just under a million per year and in a few months we should cross that threshold. That is a significant number for many reasons. Lets start with a large enough pool of patients so in 3 more years we will get the final results of the real risks involved with Belviq, which will turn out to be none. Our 5 year study is going to reveal that Belviq was everything the clinical studies proved it to be. But by then we will have Belviq once daily for smoking, drug addictions, weight loss, NASH, pre diabetics that need to control their cravings. We should have Belviq now selling in several countries all around the world including EU.
By that time we will have PAH, Temanogre and pain completing Phase III and moving for NDA
It just meant that instead of Arena investors getting to cash in for a very large profit in the first 2 years we will have to wait for 2 to 3 more years. But do not kid yourself, this science and this pipeline has a lot of value... Arena is not a one hit wonder, but I will be glad when Jack retires and the new CEO replaces Miss Audet and Miss Hoffman.